CGTX PRESS-RELEASE SEC Filing Analysis

Latest settled — T+5d

CGTX ▲ +3.20% at T+5d

NEUTRAL call ✓ call won +3.20% · α vs SPY +5.95% · entry $1.25 → $1.29

Next anchor: T+20d in 17d

Currently $1.21 · -3.20% from $1.25 entry

Entry anchored
May 29, 03:46 PM ET
via Databento tick

T+1d

+8.00%

call +8.00% · α +7.86%

$1.35

settled 11d ago

T+5d

+3.20%

call +3.20% · α +5.95%

$1.29

settled 5d ago

T+20d

—

call — · α —

—

in 17d

T+60d

—

call — · α —

—

in 2mo

Price Chart

Loading chart...

Executive Summary

Cognition Therapeutics announced its CEO will present at the Jefferies Global Healthcare Conference (June 4) and H.C. Wainwright Neuro Perspectives Summit (on-demand from June 15) to provide updates on the planned registration program for zervimesine in DLB psychosis. No financial data was disclosed; the press release is a routine corporate update.

Actionable Insight

Monitor the CEO presentations for any updates on the DLB psychosis registration program, but no immediate trading catalyst is expected from this announcement alone.

Key Facts

CEO Lisa Ricciardi to present at 2026 Jefferies Global Healthcare Conference on June 4 at 1:25 p.m. ET.
CEO to present at H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit on-demand beginning June 15 at 8:00 a.m. ET.
Company plans to advance zervimesine (CT1812) into a late-stage clinical trial for DLB psychosis following positive Phase 2 SHIMMER study results.
No new financial or clinical data released in this announcement.

Financial Impact

No financial impact from this press release.

Risk Factors

Clinical trial risks for zervimesine in DLB psychosis.
Regulatory uncertainties regarding the registration program.
Dependence on future financing for clinical development.

Market Snapshot

Exchange

Nasdaq

Sector

Biological Products, (No Diagnostic Substances)

Analyst Consensus

90% bullish (10 analysts)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3304237

10 reports for CGTX

T+1T+5T+20T+60

75% Hit rate 3 of 4 directional calls best @ T+60▲ +16.98%Mar 2, 2026

Filters

Reports for CGTX — sortable, filterable
	Type				Now
Jun 4, 2026 8d ago	8-K NEUTRAL ★ 4/10	$1.36 $1.29	▼ −5.15%	▼ −2.55%	$1.21 (−11.03%)
Jun 1, 2026 11d ago	Press Release NEUTRAL ★ 2/10	$1.25 $1.35	▲ +8.00%	▲ +7.86%	$1.21 (−3.20%)
May 21, 2026 22d ago	Press Release BULLISH ★ 6/10	$1.25 $1.26	▲ +0.80%	▲ +0.35%	$1.21 (−3.20%)
May 14, 2026 29d ago	Press Release NEUTRAL ★ 3/10	$1.20 $1.14	▼ −5.00%	▼ −3.77%	$1.21 (+0.83%)
May 7, 2026 5w ago	8-K NEUTRAL ★ 5/10	$1.21 $1.18	▼ −2.48%	▼ −2.71%	$1.21 (+0.00%)
Apr 16, 2026 8w ago	Insider Cluster BULLISH ★ 5/10	$1.11 $1.19	▲ +7.21%	▲ +5.99%	$1.21 (+9.01%)
Mar 26, 2026 11w ago	Press Release NEUTRAL ★ 5/10	$1.08 $0.7300	▼ −32.41%	▼ −30.73%	$1.21 (+12.04%)
Mar 23, 2026 11w ago	Press Release NEUTRAL ★ 3/10	$1.13 $1.10	▼ −2.65%	▼ −2.30%	$1.21 (+7.08%)
Mar 17, 2026 12w ago	Press Release BULLISH ★ 8/10	$1.15 $1.10	▼ −4.35%	▼ −2.95%	$1.21 (+5.22%)
Mar 2, 2026 14w ago	Press Release BULLISH ★ 8/10	$1.06 $1.02	▼ −3.77%	▼ −2.86%	$1.21 (+14.15%)

US Market Status

Market Closed — Opens Mon (52h 22m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access